131 |
Lokalisierung und Charakterisierung Foxp3+ regulatorischer T-Zellen bis zu 30 Tage nach mechanischer und ischämischer Läsion des GehirnsStubbe, Tobias 14 January 2014 (has links)
Nach einer Läsion im Gehirn kommt es trotz der Bildung autoreaktiver T-Zellen zu keiner autoimmunen Neuropathologie. Foxp3+ regulatorische T-Zellen (Tregs) vermitteln möglicherweise Immuntoleranz nach zerebraler Läsion. Deswegen wurde in dieser Studie die Rolle der Tregs 7, 14 und 30 Tage nach einem transienten Verschluss der mittleren Hirnarterie (MCAO), einem Modell für ischämischen Schlaganfall, und nach entorhinaler Kortexläsion (ECL) in der Maus untersucht. Durchflusszytometrisch wurde in beiden Modellen 14 und 30 Tage nach Läsion eine Akkumulation der Tregs in der ipsilateralen Hemisphäre beobachtet. Mikroskopisch wurden an der Läsion Zellkontakte der Tregs mit antigenpräsentierenden Zellen beobachtet. Weitere Experimente wurden ausschließlich nach MCAO durchgeführt. Am Tag 14 und 30 war in der ipsilateralen Hemisphäre eine Akkumulation der Mikroglia zu beobachten. Makrophagen und dendritische Zellen wurden an den Tagen 7, 14 und 30 detektiert. Am Tag 7 und 14 waren ipsilateral im Gehirn ca. 60 % der Tregs positiv für den Proliferationsmarker Ki-67. In zwei Versuchsansätzen wurden naive CD45RBhigh/CD4+ Zellen aus lymphatischen Organen von Foxp3EGFP Mäusen, mit Wildtyp T-Zellrezeptor (TCR), oder 2D2.Foxp3EGFP Mäusen, mit TCR spezifisch gegen Myelin-Oligodendrozyten-Glykoprotein, isoliert. Die Zellen wurden einen Tag vor MCAO in RAG1-/- Mäuse, welche keine adulten T- und B-Zellen besitzen, transferiert. Am Tag 14 nach MCAO war in den RAG1-/- Mäusen keine de novo Induktion Foxp3EGFP+ Tregs zu beobachten. CD25+ Tregs wurden durch die Injektion eines Antikörpers gegen CD25 depletiert, um deren Wirkung nach MCAO zu untersuchen. Nach Depletion konnte bis zu 27 Tage nach MCAO keine Veränderung des Läsionsvolumen und des Gangverhaltens beobachtet werden. In dieser Studie wurde im Gehirn eine späte Präsenz und Proliferation Foxp3+ Tregs nach Läsion nachgewiesen. Mikroglia und periphere Immunzellen sind langfristig an Immunvorgängen im lädierten Gehirn beteiligt. / After brain lesion autoreactive T cells specific against brain antigens are expanded, but no delayed autoimmune neuropathology evolves. Immune suppressive CD4+/Foxp3+ regulatory T cells (Tregs) could have an important role in maintaining immune tolerance in the lesioned brain. Therefore, this study sought to analyse the role of Tregs in mice 7, 14 and 30 days after transient middle cerebral artery occlusion (MCAO), a model for ischemic stroke, and entorhinal cortex lesion (ECL). An accumulation of Tregs was detected in the brain by flow cytometry in both models at days 14 and 30 after lesion. Using immunohistochemistry Tregs were found in close cell-cell contact with antigen presenting cells at the lesion site. Further experiments were performed solely with MCAO. On days 14 and 30 after MCAO a strong accumulation of microglia occurred in the ipsilesional hemisphere. Macrophages and dendritic cells were found ipsilesionally on days 7, 14 and 30. On days 7 and 14 about 60% of Tregs were positive for the proliferation marker Ki-67 in the lesioned hemisphere. In two different setups naïve CD45RBhigh/CD4+ cells were isolated from lymphatic organs of Foxp3EGFP mice, carrying a wild type T cell receptor (TCR), or 2D2.Foxp3EGFP mice, carrying a TCR specific for myelin oligodendrocyte glycoprotein. One day before MCAO naïve CD45RBhigh/CD4+ cells depleted of Foxp3EGFP+ Tregs were transferred into RAG1-/- mice, which lack adult B and T cells. At day 14 after MCAO no de novo generation of Foxp3EGFP+ Tregs was observed. The effects of Tregs on stroke outcome were tested by depleting CD25+/Foxp3EGFP+ Tregs with an antibody against CD25. After depletion no effects on lesion volumes and gait parameters were detected up to 27 days following MCAO. The present study demonstrates for the first time a sustained presence and proliferation of Tregs in the lesioned brain. Local microglia and peripheral immune cells are involved in long-lasting immune processes following brain lesion.
|
132 |
Reversal of the neurological deficit in acute stroke with the signal of efficacy trial of auto-BPAP to limit damage from suspected sleep apnea (Reverse-STEAL): study protocol for a randomized controlled trialKepplinger, Jessica, Barlinn, Kristian, Kolieskova, Stanislava, Shahripour, Reza Bavarsad, Pallesen, Lars-Peder, Schrempf, Wiebke, Grählert, Xina, Schwanebeck, Uta, Sisson, April, Zerna, Charlotte, Pütz, Volker, Reichmann, Heinz, Albright, Karen C., Alexandrov, Anne W., Vosko, Milan, Mikulik, Robert, Bodechtel, Ulf, Alexandrov, Andrei V. 22 January 2014 (has links) (PDF)
Background: Although the negative impact of sleep apnea on the clinical course of acute ischemic stroke (AIS) is well known, data regarding non-invasive ventilation in acute patients are scarce. Several studies have shown its tolerability and safety, yet no controlled randomized sequential phase studies exist that aim to establish the efficacy of early non-invasive ventilation in AIS patients.
Methods/design: We decided to examine our hypothesis that early non-invasive ventilation with auto-titrating bilevel positive airway pressure (auto-BPAP) positively affects short-term clinical outcomes in AIS patients. We perform a multicenter, prospective, randomized, controlled, third rater- blinded, parallel-group trial. Patients with AIS with proximal arterial obstruction and clinically suspected sleep apnea will be randomized to standard stroke care alone or standard stroke care plus auto-BPAP. Auto-BPAP will be initiated within 24 hours of stroke onset and performed for a maximum of 48 hours during diurnal and nocturnal sleep. Patients will undergo unattended cardiorespiratory polygraphy between days three and five to assess sleep apnea. Our primary endpoint will be any early neurological improvement on the NIHSS at 72 hours from randomization. Safety, tolerability, short-term and three-months functional outcomes will be assessed as secondary endpoints by un-blinded and blinded observers respectively.
Discussion: We expect that this study will advance our understanding of how early treatment with non-invasive ventilation can counterbalance, or possibly reverse, the deleterious effects of sleep apnea in the acute phase of ischemic stroke. The study will provide preliminary data to power a subsequent phase III study.
|
133 |
Effective Treatment with Abciximab for Consecutive Bilateral Middle Cerebral Artery OcclusionPütz, Volker, Weise, Matthias, Kummer, Rüdiger von, Gahn, Georg 26 February 2014 (has links) (PDF)
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
|
134 |
Risikoprädiktion für sehr frühen Reinfarkt, Tod und Progression nach ischämischem Schlaganfall / Risk prediction of very early recurrence, death and progression after acute ischaemic strokeMaier, Ilko 20 January 2014 (has links)
No description available.
|
135 |
Transcranial direct current stimulation (tDCS) for improving capacity in activities and arm function after stroke: a network meta-analysis of randomised controlled trialsElsner, Bernhard, Kwakkel, Gert, Kugler, Joachim, Mehrholz, Jan 06 June 2018 (has links) (PDF)
Background:
Transcranial Direct Current Stimulation (tDCS) is an emerging approach for improving capacity in activities of daily living (ADL) and upper limb function after stroke. However, it remains unclear what type of tDCS
stimulation is most effective. Our aim was to give an overview of the evidence network regarding the efficacy and safety of tDCS and to estimate the effectiveness of the different stimulation types.
Methods:
We performed a systematic review of randomised trials using network meta-analysis (NMA), searching the following databases until 5 July 2016: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED, Web of Science, and four other databases. We included studies with adult people with stroke. We compared any kind of active tDCS (anodal, cathodal, or dual, that is applying anodal and cathodal tDCS concurrently) regarding improvement of our primary outcome of ADL capacity, versus control, after stroke.
PROSPERO ID: CRD42016042055.
Results:
We included 26 studies with 754 participants. Our NMA showed evidence of an effect of cathodal tDCS in improving our primary outcome, that of ADL capacity (standardized mean difference, SMD = 0.42; 95% CI 0.14 to 0.70). tDCS did not improve our secondary outcome, that of arm function, measured by the Fugl-Meyer upperextremity assessment (FM-UE). There was no difference in safety between tDCS and its control interventions, measured by the number of dropouts and adverse events.
Conclusion:
Comparing different forms of tDCS shows that cathodal tDCS is the most promising treatment option to improve ADL capacity in people with stroke.
|
136 |
Einfluss von Anti-NMDA-Rezeptor-NR1-Autoantikörpern bei ApoE4-bedingter chronischer Beeinträchtigung der Blut-Hirn-Schranke / Role of anti-NMDA-receptor NR1 autoantibodies depending on ApoE4 related chronic impairment of the blood brain barrierZerche, Maria 19 July 2018 (has links)
No description available.
|
137 |
Anwendbarkeit des Alberta Stroke Program Early CT Score (ASPECTS) anhand multimodaler CT-Bildgebung in der Schlaganfallfrühdiagnostik und dessen Fähigkeit zur Vorhersage des klinischen Behandlungsergebnisses für Patienten, welche durch Thrombusextraktion durch Aspiration behandelt werden. / Applicability of the Alberta Stroke Program Early CT Scale (ASPECTS) based on Multimodal Computed Tomography for Early Stroke Imaging and its Ability to Predict Clinical Outcomes of Patients Treated With Aspiration ThrombectomyReinhardt, Lars 10 January 2017 (has links)
Der ischämische Schlaganfall ist ein ernstzunehmendes Ereignis, welches rascher Rekanalisationstherapie bedarf. Hierfür stehen mehrere Therapieansätze zur Verfügung. Bildgebungsgestützte Patientenselektion zur individuell geeigneten Therapie kann das abschließende klinische Behandlungsergebnis des einzelnen Patienten maßgeblich verbessern. Der Alberta Stroke Program Early CT Score (ASPECTS), eine einfach und schnell anwendbare 10-Punkte-Skala zur Auswertung von Schädel-CT-Untersuchungen, wurde bereits als hilfreicher Prädiktor für das klinische Behandlungsergebnis nach erfolgreicher thrombolytischer Therapie identifiziert. Ein Nachteil der nativen Schädel-CT ist, dass der Infarktkern erst mit mehreren Stunden Verzögerung erkennbar wird. Das aktuelle Ausmaß des Infarktkerns kann durch Bestimmung des zerebralen Blutvolumens (CBV) anhand von Perfusions-CT-Untersuchungen schneller ermittelt werden.
Diese Studie analysiert retrospektiv multimodale CT-Bildgebung einer Patientenkohorte von 51 Patienten mit akutem ischämischen Schlaganfall aufgrund eines Verschlusses im M1-Segment der Arteria cerebri media bezüglich des Behandlungsergebnisses nach endovaskulärer Therapie. Die CT-Daten wurden mit kommerzieller Computersoftware nachverarbeitet. Zwei erfahrene Neuroradiologen werteten getrennt voneinander Nativ- und Perfusions-CT-Daten mithilfe des ASPECTS aus. Die Befunde der Patientengruppe mit schlechtem klinischen Behandlungsergebnis wurden mit denen der Gruppe mit gutem Ergebnis verglichen. Variablen, welche statistisch signifikante Unterschiede aufwiesen, wurden daraufhin untersucht.
Zwischen den Ergebnissen der Rekanalisationstherapie, den Zeitintervallen oder den nativen CT-ASPECTS-Ergebnissen beider Gruppen bestand kein signifikanter Unterschied. Signifikant unterschieden sich die Gruppen im Hinblick auf das Patientenalter. Die übrigen Basischarakteristika der beiden Patientengruppen unterschieden sich nicht signifikant. Es ergaben sich weiterhin signifikante Unterschiede im Bezug auf den ASPECTS für zerebralen Blutfluss (CBF-ASPECTS) und die Differenz zwischen ASPECTS für zerebrales Blutvolumen (CBV-ASPECTS) und CBF-ASPECTS [Δ(CBV - CBF)-ASPECTS]. Für CBV-ASPECTS > 7 konnte die höchste Sensitivität (84 %) und Spezifität (79 %) zur Voraussage eines guten klinischen Behandlungsergebnisses ermittelt werden.
Diese Studie zeigt, dass durch ASPECTS ausgewertete CT-Perfusionsparameter eine optimale Voraussagekraft für das klinische Behandlungsergebnis nach erfolgreicher Rekanalisationstherapie besitzen und diese sensitiver und spezifischer als der native CT-ASPECTS sind. Der ASPECTS erlaubt einen einfachen und schnellen quantitativen Überblick über die tatsächliche aktuelle Situation des einzelnen Patienten. Die Berücksichtigung dieser Parameter bei Therapieentscheidungen könnte helfen, Patienten der geeigneten Therapie zuzuführen und die Anzahl vergeblicher Rekanalisationsbehandlungen zu reduzieren.
|
138 |
Reversal of the neurological deficit in acute stroke with the signal of efficacy trial of auto-BPAP to limit damage from suspected sleep apnea (Reverse-STEAL): study protocol for a randomized controlled trialKepplinger, Jessica, Barlinn, Kristian, Kolieskova, Stanislava, Shahripour, Reza Bavarsad, Pallesen, Lars-Peder, Schrempf, Wiebke, Grählert, Xina, Schwanebeck, Uta, Sisson, April, Zerna, Charlotte, Pütz, Volker, Reichmann, Heinz, Albright, Karen C., Alexandrov, Anne W., Vosko, Milan, Mikulik, Robert, Bodechtel, Ulf, Alexandrov, Andrei V. 22 January 2014 (has links)
Background: Although the negative impact of sleep apnea on the clinical course of acute ischemic stroke (AIS) is well known, data regarding non-invasive ventilation in acute patients are scarce. Several studies have shown its tolerability and safety, yet no controlled randomized sequential phase studies exist that aim to establish the efficacy of early non-invasive ventilation in AIS patients.
Methods/design: We decided to examine our hypothesis that early non-invasive ventilation with auto-titrating bilevel positive airway pressure (auto-BPAP) positively affects short-term clinical outcomes in AIS patients. We perform a multicenter, prospective, randomized, controlled, third rater- blinded, parallel-group trial. Patients with AIS with proximal arterial obstruction and clinically suspected sleep apnea will be randomized to standard stroke care alone or standard stroke care plus auto-BPAP. Auto-BPAP will be initiated within 24 hours of stroke onset and performed for a maximum of 48 hours during diurnal and nocturnal sleep. Patients will undergo unattended cardiorespiratory polygraphy between days three and five to assess sleep apnea. Our primary endpoint will be any early neurological improvement on the NIHSS at 72 hours from randomization. Safety, tolerability, short-term and three-months functional outcomes will be assessed as secondary endpoints by un-blinded and blinded observers respectively.
Discussion: We expect that this study will advance our understanding of how early treatment with non-invasive ventilation can counterbalance, or possibly reverse, the deleterious effects of sleep apnea in the acute phase of ischemic stroke. The study will provide preliminary data to power a subsequent phase III study.
|
139 |
Normothermia after decompressive surgery for space-occupying middle cerebral artery infarction: a protocol-based approachRahmig, Jan, Kuhn, Matthias, Neugebauer, Hermann, Jüttler, Eric, Reichmann, Heinz, Schneider, Hauke 05 June 2018 (has links)
Background
Moderate hypothermia after decompressive surgery might not be beneficial for stroke patients. However, normothermia may prove to be an effective method of enhancing neurological outcomes. The study aims were to evaluate the application of a pre-specified normothermia protocol in stroke patients after decompressive surgery and its impact on temperature load, and to describe the functional outcome of patients at 12 months after treatment.
Methods
We analysed patients with space-occupying middle cerebral artery (MCA) infarction treated with decompressive surgery and a pre-specified temperature management protocol. Patients treated primarily with device-controlled normothermia or hypothermia were excluded. The individual temperature load above 36.5 °C was calculated for the first 96 h after hemicraniectomy as the Area Under the Curve, using °C x hours. The effect of temperature load on functional outcome at 12 months was analysed by logistic regression.
Results
We included 40 stroke patients treated with decompressive surgery (mean [SD] age: 58.9 [10.1] years; mean [SD] time to surgery: 30.5 [16.7] hours). Fever (temperature > 37.5 °C) developed in 26 patients during the first 96 h after surgery and mean (SD) temperature load above 36.5 °C in this time period was 62,3 (+/− 47,6) °C*hours. At one year after stroke onset, a moderate to moderately severe disability (modified Rankin Scale score of 3 or 4) was observed in 32% of patients, and a severe disability (score of 5) in 37% of patients, respectively. The lethality in the cohort at 12 months was 32%. The temperature load during the first 96 h was not an independent predictor for 12 month lethality (OR 0.986 [95%-CI:0.967–1.002]; p < 0.12).
Conclusions
Temperature control in surgically treated patients with space-occupying MCA infarction using a pre-specified protocol excluding temperature management systems resulted in mild hyperthermia between 36.8 °C and 37.2 °C and a low overall temperature load. Future prospective studies on larger cohorts comparing different strategies for normothermia treatment including temperature management devices are needed.
|
140 |
Transcranial direct current stimulation (tDCS) for improving capacity in activities and arm function after stroke: a network meta-analysis of randomised controlled trialsElsner, Bernhard, Kwakkel, Gert, Kugler, Joachim, Mehrholz, Jan 06 June 2018 (has links)
Background:
Transcranial Direct Current Stimulation (tDCS) is an emerging approach for improving capacity in activities of daily living (ADL) and upper limb function after stroke. However, it remains unclear what type of tDCS
stimulation is most effective. Our aim was to give an overview of the evidence network regarding the efficacy and safety of tDCS and to estimate the effectiveness of the different stimulation types.
Methods:
We performed a systematic review of randomised trials using network meta-analysis (NMA), searching the following databases until 5 July 2016: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED, Web of Science, and four other databases. We included studies with adult people with stroke. We compared any kind of active tDCS (anodal, cathodal, or dual, that is applying anodal and cathodal tDCS concurrently) regarding improvement of our primary outcome of ADL capacity, versus control, after stroke.
PROSPERO ID: CRD42016042055.
Results:
We included 26 studies with 754 participants. Our NMA showed evidence of an effect of cathodal tDCS in improving our primary outcome, that of ADL capacity (standardized mean difference, SMD = 0.42; 95% CI 0.14 to 0.70). tDCS did not improve our secondary outcome, that of arm function, measured by the Fugl-Meyer upperextremity assessment (FM-UE). There was no difference in safety between tDCS and its control interventions, measured by the number of dropouts and adverse events.
Conclusion:
Comparing different forms of tDCS shows that cathodal tDCS is the most promising treatment option to improve ADL capacity in people with stroke.
|
Page generated in 0.0351 seconds